This course has expired. View available courses.
Diabetes, Nephrology
Management of the Complex Type 2 Diabetes Patient with Kidney Disease | Module 2 – Cardiorenal Protection in Type 2 Diabetes: The Role of SGLT2i and GLP1-RA
This video helps pharmacists understand the role of sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA) in cardiorenal protection for people with type 2 diabetes. The goal is to review the use of SGLT2i and GLP1-RA for these patients, and help pharmacists apply effective counselling for the management of people with type 2 diabetes and chronic kidney disease.
This learning activity has received financial support from Janssen Inc in the form of educational grant
DURATION
15 min
PROFESSION
Pharmacy
# OF CREDITS
0.33
ACCREDITATION
CCCEP
EXPIRY DATE
2023-08-16
This video helps pharmacists understand the role of sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP1-RA) in cardiorenal protection for people with type 2 diabetes. The goal is to review the use of SGLT2i and GLP1-RA for these patients, and help pharmacists apply effective counselling for the management of people with type 2 diabetes and chronic kidney disease.
This learning activity has received financial support from Janssen Inc in the form of educational grant
Faculty
Rick Siemens, BScPharm, B.Sc. Biol., CDE, CPT, APA – Pharmacist
Parveen Gill, BScPharm, CDE, CAE, CTH, APA – Pharmacist
Anita Brown, BScPharm, CDE – Pharmacist
John Papastergiou, BScPharm, B.Sc. – Pharmacist
Learning objectives
- Understand the role of SGLT2i and GLP1-RA in cardiorenal protection of people with type 2 diabetes
- Describe the mechanism of action of SGLT2i and GLP1-RA for cardiorenal protection in people with type 2 diabetes
- Illustrate the use of pharmacotherapy for cardiorenal protection in people with type 2 diabetes
Accreditation
CCCEP File Number: 1066-2022-3453-I-P